Intellectual Property: Last chance for Europe’s biotech pioneers

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs – despite the protests of the biotech pioneers who created them.


Comments are closed.

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: